Hemophilia B Treatments
Find Hemophilia B Treatments
Brand Name
Hympavzi
Generic Name
Marstacimab-Hncq
View Brand Information FDA approval date: November 05, 2024
Form: Injection
What is Hympavzi (Marstacimab-Hncq)?
HYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with: hemophilia A without factor VIII inhibitors, or, hemophilia B without factor IX inhibitors. HYMPAVZI is a tissue factor pathway inhibitor antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:, hemophilia A without factor VIII inhibitors, or, hemophilia B without factor IX inhibitors.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
There is no clinical trials being done for this treatment